Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 146 of 5804
-
New drug combo aims to spare esophagus in cancer patients
Disease control Recruiting nowThis is a multicenter phase II clinical study to explore the efficacy, safety, and organ preservation feasibility of camrelizumab in combination with chemotherapy for resectable esophageal squamous carcinoma in patients with histologically and pathologically confirmed resectable …
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Radiation boosts CAR-T: new hope for tough lymphoma?
Disease control Recruiting nowThis study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to FDA approved (commercially available) infusion in patients with Relapsed or refractory (R/R) non-Hodgkin lymphoma.
Phase: PHASE1, PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New PET-MRI tracer could sharpen prostate cancer biopsy accuracy
Diagnosis Recruiting nowThis phase II trial evaluates an imaging technique called 18F-rhPSMA-7.3 positron emission tomography (PET)-multiparametric (mp) magnetic resonance imaging (MRI) in identifying tumor tissue in men suspected to have prostate cancer. This clinical trial also seeks to determine if t…
Phase: PHASE2 • Sponsor: Emory University • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
New cell therapy GT719 targets tough blood cancers in early trial
Disease control Recruiting nowThis study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymph…
Phase: PHASE1, PHASE2 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 26, 2026 18:26 UTC
-
New oral pill HPP737 takes on psoriasis in Head-to-Head trial
Disease control CompletedThe goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737. The main questions it aims to answer are: Does drug HPP737 improve psoriasis severity compared to an activ…
Phase: PHASE3 • Sponsor: Newsoara Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New Heart-Lung device could save kids with severe heart failure
Disease control Recruiting nowThere are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to: 1. To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for …
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Smarter prostate screening: a new risk score aims to cut unnecessary biopsies
Diagnosis ENROLLING_BY_INVITATIONClarityDX Prostate builds upon the utility of total and free PSA as well as simple clinical features in a decision support model to determine a patient's risk of having clinically significant prostate cancer. The highly accurate ClarityDX Prostate risk score enables clinicians an…
Phase: NA • Sponsor: Nanostics • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
Can less be more? new trial aims to cut harsh side effects in HPV throat cancer treatment
Disease control Recruiting nowHead and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\>90%) are caused by the human papillomavirus (HPV) and are oft…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay longer
Disease control Recruiting nowThe main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standar…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for kids with MS: Head-to-Head drug trial launches
Disease control Recruiting nowThe purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hepatitis c pill aims to cut treatment time in half
Disease control OngoingThe purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Phase: PHASE3 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could an immune booster keep early lung cancer from returning?
Disease control Recruiting nowThis phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New Bladder-Sparing combo could change how we treat aggressive bladder cancer
Disease control Recruiting nowThis phase Ib/II trial studies the side effects, best dose, and effectiveness of enfortumab vedotin (EV) in combination with pembrolizumab and radiation therapy for treating patients with muscle invasive bladder cancer. Standard of care treatment for muscle invasive bladder cance…
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for tough esophageal cancer: experimental drug takes on chemo in major trial
Disease control Recruiting nowThis study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic the…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Triple attack on pancreatic cancer: heat, chemo, and immunotherapy combined in new trial
Disease control Recruiting nowThe purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPD…
Phase: PHASE2 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jun 26, 2026 16:26 UTC
-
New shot could tame COPD Flare-Ups in severe patients
Disease control Recruiting nowA Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for advanced bladder cancer: experimental drug takes on chemo in major trial
Disease control Recruiting nowThis trial is a registered phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic urothelial carcinoma after failure of PD-1/PD-L1 monoclonal antibody and platinum-based chemotherapy.
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New pill could ease painful skin condition
Disease control OngoingThe purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take on autoimmune diseases
Disease control OngoingThis is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
Phase: NA • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated Jun 26, 2026 13:50 UTC
-
Could a One-Time immune cell treatment tame severe vasculitis?
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC